Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 3, 2017, Pages 262-271

  Liao, Haotian ^a   Tan, Ping ^a   Zhu, Zexin ^a   Yan, Xiaokai ^a   Huang, Jiwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; IMMUNOSUPPRESSIVE AGENT; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PERITONITIS; COMBINATION DRUG THERAPY; DEATH; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GRAFT RECIPIENT; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LIVER FIBROSIS; LIVER GRAFT; META ANALYSIS; NEUTROPENIA; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; GENOTYPE; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C; HUMANS; IMIDAZOLES; LIVER TRANSPLANTATION; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 85009165650     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.12.001     Document Type: Article

References (35)

1. Kim, W.R., Smith, J.M., Skeans, M.A., et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant 14:Suppl. 1 (2014), 69–96.
2. Adam, R., Karam, V., Delvart, V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 57:3 (2012), 675–688.
3. Merion, R.M., Current status and future of liver transplantation. Semin Liver Dis 30:4 (2010), 411–421.
4. Brown, R.S., Hepatitis C and liver transplantation. Nature 436:7053 (2005), 973–978.
5. Gane, E.J., Portmann, B.C., Naoumov, N.V., et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334:13 (1996), 815–820.
6. Berenguer, M., Prieto, M., Rayon, J.M., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 32:4 Pt 1 (2000), 852–858.
7. Berenguer, M., Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49:2 (2008), 274–287.
8. Wang, C.S., Ko, H.H., Yoshida, E.M., Marra, C.A., Richardson, K., Interferon-based combination antiviral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 6:7 (2006), 1586–1599.
9. Xirouchakis, E., Triantos, C., Manousou, P., et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 15:10 (2008), 699–709.
10. Coilly, A., Roche, B., Dumortier, J., et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 60:1 (2014), 78–86.
11. Coilly, A., Dumortier, J., Botta-Fridlund, D., et al. Multicenter experience with boceprevir or telaprevir to treat hepatitis c recurrence after liver transplantation: when present becomes past, what lessons for future?. PloS one, 10(9), 2015, e0138091.
12. Gao, M., Nettles, R.E., Belema, M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:7294 (2010), 96–100.
13. Sofia, M.J., Bao, D., Chang, W., et al. Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53:19 (2010), 7202–7218.
14. Lam, A.M., Espiritu, C., Bansal, S., et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:6 (2012), 3359–3368.
15. Nettles, R.E., Gao, M., Bifano, M., et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54:6 (2011), 1956–1965.
16. Sulkowski, M.S., Gardiner, D.F., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:3 (2014), 211–221.
17. Coilly, A., Fougerou-Leurent, C., de Ledinghen, V., et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation – the CO23 ANRS CUPILT study. J Hepatol 65:4 (2016), 711–718.
18. Fontana, R.J., Brown, R.S. Jr., Moreno-Zamora, A., et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 22:4 (2016), 446–458.
19. McPhee, F., Hernandez, D., Zhou, N., et al. Baseline HCV NS5A resistance-associated variants do not impact SVR12 rates in non-cirrhotic and post-liver transplant patients with genotype 1 infection treated with daclatasvir and sofosbuvir with or without ribavirin for 12 weeks: an integrated analysis. Hepatology 62 (2015), 560A–561A.
20. Herzer, K., Welzel, T.M., Ferenci, P., et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: interim results of a multicenter compassionate use program. Hepatology, 62, 2015, 341A.
21. Poordad, F., Schiff, E.R., Vierling, J.M., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63:5 (2016), 1493–1505.
22. Leroy, V., Dumortier, J., Coilly, A., et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 13:11 (2015), 1993–2001 [e1991–1992].
23. Foster, G.R., Irving, W.L., Cheung, M.C., et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64:6 (2016), 1224–1231.
24. Pungpapong, S., Aqel, B., Leise, M., et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 61:6 (2015), 1880–1886.
25. Chung, R.T., Davis, G.L., Jensen, D.M., et al. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:3 (2015), 932–954.
26. Charlton, M., Gane, E., Manns, M.P., et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 148:1 (2015), 108–117.
27. Asselah, T., Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol 61:2 (2014), 435–438.
28. Reddy, K.R., Bourliere, M., Sulkowski, M., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62:1 (2015), 79–86.
29. Koh, C., Liang, T.J., What is the future of ribavirin therapy for hepatitis C?. Antiviral Res 104 (2014), 34–39.
30. Ojo, A.O., Held, P.J., Port, F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:10 (2003), 931–940.
31. Flamm, S., Bacon, B., Curry, M., et al. Ledipasvir/sofosbuvir ± ribavirin in HCV post-transplant patients: real-world heterogeneous population from the trio network. J Hepatol 1 (2016), S822–S823.
32. Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:3 (2015), 649–659.
33. Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 16:6 (2016), 685–697.
34. Ciesek, S., Proske, V., Otto, B., et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis 18:3 (2016), 326–332.
35. Kwo, P.Y., Mantry, P.S., Coakley, E., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 371:25 (2014), 2375–2382.